Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The PI3K Pathway in Human Disease
David A. Fruman, Honyin Chiu, Benjamin D. Hopkins, et al.
Cell (2017) Vol. 170, Iss. 4, pp. 605-635
Open Access | Times Cited: 2145

Showing 1-25 of 2145 citing articles:

The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj, Brendan D. Manning
Nature reviews. Cancer (2019) Vol. 20, Iss. 2, pp. 74-88
Open Access | Times Cited: 1507
Targeting ferroptosis as a vulnerability in cancer
Guang Lei, Li Zhuang, Boyi Gan
Nature reviews. Cancer (2022) Vol. 22, Iss. 7, pp. 381-396
Open Access | Times Cited: 1396
Reprogramming of fatty acid metabolism in cancer
Nikos Koundouros, George Poulogiannis
British Journal of Cancer (2019) Vol. 122, Iss. 1, pp. 4-22
Open Access | Times Cited: 1157
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1127
Facing up to the global challenges of ageing
Linda Partridge, Joris Deelen, P. Eline Slagboom
Nature (2018) Vol. 561, Iss. 7721, pp. 45-56
Closed Access | Times Cited: 1083
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He, Miao Sun, Guo Geng Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 890
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 810
Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis
Jun-Mei Yi, Jiajun Zhu, Jiao Wu, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 49, pp. 31189-31197
Open Access | Times Cited: 680
Specificity, versatility, and control of TGF-β family signaling
Rik Derynck, Erine H. Budi
Science Signaling (2019) Vol. 12, Iss. 570
Open Access | Times Cited: 611
KRAS mutation: from undruggable to druggable in cancer
Lamei Huang, Zhixing Guo, Fang Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 593
Branched Chain Amino Acids: Beyond Nutrition Metabolism
Cunxi Nie, Ting He, Wenju Zhang, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 4, pp. 954-954
Open Access | Times Cited: 590
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins, Chantal Pauli, Xing Du, et al.
Nature (2018) Vol. 560, Iss. 7719, pp. 499-503
Open Access | Times Cited: 583
Clinical implications of PTEN loss in prostate cancer
Tamara Jamaspishvili, David M. Berman, Ashley E. Ross, et al.
Nature Reviews Urology (2018) Vol. 15, Iss. 4, pp. 222-234
Open Access | Times Cited: 525
The relation between PI3K/AKT signalling pathway and cancer
Saeed Noorolyai, Neda Shajari, Elham Baghbani, et al.
Gene (2019) Vol. 698, pp. 120-128
Closed Access | Times Cited: 495
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
Devesh Tewari, Pooja Patni, Anusha Bishayee, et al.
Seminars in Cancer Biology (2019) Vol. 80, pp. 1-17
Closed Access | Times Cited: 470
PI3K isoforms in cell signalling and vesicle trafficking
Benoît Bilanges, York Posor, Bart Vanhaesebroeck
Nature Reviews Molecular Cell Biology (2019) Vol. 20, Iss. 9, pp. 515-534
Closed Access | Times Cited: 420
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer
Nikos Koundouros, George Poulogiannis
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 356
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan, Ryan B. Corcoran
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 11, pp. 709-720
Closed Access | Times Cited: 339
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck, Matthew W. D. Perry, Jennifer R. Brown, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 10, pp. 741-769
Open Access | Times Cited: 335
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
Yue Gong, Peng Ji, Yun‐Song Yang, et al.
Cell Metabolism (2020) Vol. 33, Iss. 1, pp. 51-64.e9
Open Access | Times Cited: 326
Dietary modifications for enhanced cancer therapy
Naama Kanarek, Boryana Petrova, David M. Sabatini
Nature (2020) Vol. 579, Iss. 7800, pp. 507-517
Closed Access | Times Cited: 313
Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics
Ambika Chamoli, Abhishek Gosavi, Urjita P. Shirwadkar, et al.
Oral Oncology (2021) Vol. 121, pp. 105451-105451
Closed Access | Times Cited: 307
Anti-Inflammatory Drugs as Anticancer Agents
Silvia Zappavigna, Alessia Maria Cossu, Anna Grimaldi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2605-2605
Open Access | Times Cited: 297
Signaling Pathways Involved in the Regulation of mRNA Translation
Philippe P. Roux, Ivan Topisirović
Molecular and Cellular Biology (2018) Vol. 38, Iss. 12
Open Access | Times Cited: 281
Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
Marcus D. Goncalves, Benjamin D. Hopkins, Lewis C. Cantley
New England Journal of Medicine (2018) Vol. 379, Iss. 21, pp. 2052-2062
Closed Access | Times Cited: 274
Page 1 - Next Page

Scroll to top